Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Prof. Katja Weisel
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Prof. Katja Weisel is deputy director and associate professor at the University Medical Center Hamburg-Eppendorf (Oncology, Hematology and BMT with the Department of Pneumology), Hamburg, Germany. She is also co-director of the University Cancer Center Hamburg, Germany, and is head of the myeloma programme. read more
Prof. Weisel’s myeloma research interests focus on treatment optimization for high-risk myeloma, renally impaired myeloma patients, refractory myeloma patients and radiographic methods to monitor myeloma disease. She is a member of the steering committee of the German-speaking Multiple Myeloma Group (GMMG) where she is lead investigator of GMMG trials. Prof. Weisel has more than 100 publications on multiple myeloma treatment and biology.
Prof. Katja Weisel discloses: Advisory board or panel fees from AbbVie, Amgen, BeiGene, BMS/Celgene, GSK, Janssen, Karyopharm, Oncopeptides, Pfizer, Regeneron, Roche Pharma, Sanofi, Stemline/Menarini and Takeda. Consultant fees from AbbVie, Adaptive Biotech, Amgen, AstraZeneca, BeiGene, BMS/Celgene, GSK, Janssen, Karyopharm, Novartis, Oncopeptides, Pfizer, Regeneron, Roche Pharma, Sanofi, Stemline/Menarini and Takeda. Grants/research support from AbbVie, Amgen, BMS/Celgene, GSK and Sanofi.
Dr Nisha Joseph
Emory University School of Medicine, Atlanta, GA, USA
Dr Nisha Joseph is an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, Atlanta, GA, USA. She is board certified in haematology and medical oncology, specializing in plasma cell disorders and bone marrow transplant. Dr Joseph was named the first H.J. Khoury Fellowship in Leukemia and Bone Marrow Transplantation. read more
Dr Joseph received her medical degree from the Ohio State University School of Medicine in Columbus, OH, USA. She completed both her residency in internal medicine and her fellowship in haematology and medical oncology at Emory University, where she served as chief fellow in her final year.
Dr Nisha Joseph discloses: Advisory board or panel fees from BMS, GSK, Johnson & Johnson Oncology and Legend Biotech. Consultant fees from BMS and Johnson & Johnson Oncology. Grants/research support from AbbVie, BMS, Genentech, GSK, Johnson & Johnson Oncology and Sanofi.
Prof. Roman Hájek
University Hospital Ostrava, Ostrava, Czech Republic
Prof. Roman Hájek is professor of oncology in the Faculty of Medicine at the University of Ostrava, and is head of the Department of Haematooncology in the University Hospital Ostrava, in the Czech Republic. Prof Hájek is also head of the Blood Cancer Research Group – international research team. read more
Prof. Hájek has published over 600 scientific articles and book chapters, and is an editor of the European Journal of Hematology. His research interests include multiple myeloma and other monoclonal gammopathies, bone marrow transplantation and immunotherapy. Prof. Hájek is chairman and a founding member of the Czech Myeloma Group and is an investigator on more than 70 clinical trials (across phases I to III) in multiple myeloma, including some investigating experimental immunotherapy.
Prof. Roman Hájek discloses: Advisory board or panel fees from Amgen, BMS, Janssen, Sanofi and Takeda. Consultant fees from AbbVie, Amgen, BMS/Celgene, Janssen, Novartis, PharmaMar and Takeda. Grants/research support from Amgen, Celgene, Janssen, Novartis and Takeda.
